|Bid||171.40 x 300|
|Ask||176.05 x 300|
|Day's Range||172.41 - 174.72|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.50|
|Dividend & Yield||4.60 (2.67%)|
|1y Target Est||N/A|
Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. The approval was based on a development programme that demonstrated that Erelzi, a biosimilar of the drug also known as etanercept, matches its reference medicine in terms of safety, efficacy, and quality, Sandoz said in a statement on Tuesday.
Regeneron Pharmaceuticals (REGN) has been hot this year, so hot in fact that I recommended buying its shares in May, while Jack Hough this month reiterated his bullish call from more than a year ago. Regeneron has benefited from a positive ruling in its patent battle against Amgen (AMGN), and the launch of Dupixent.
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...